Abstract
Neuroimaging studies have made a significant contribution to the efforts to identify measurable indices, or biomarkers, of addictions and their treatments. Biomarkers in addiction treatment are needed to provide targets for treatment, detect treatment subgroups, predict treatment response, and broadly improve outcomes. Neuroimaging is important to biomarkers research as it relates neural circuits to both molecular mechanisms and behavior. A focus of recent efforts in neuroimaging in addiction has been to elucidate the neural correlates associated with dimensions of functioning in substance-use and related disorders, such as cue-reactivity, impulsivity, and cognitive control, among others. These dimensions of functioning have been related to addiction treatment outcomes and relapse, and therefore, a better understanding of these dimensions and their neural correlates may help to identify brain-behavior biomarkers of treatment response. This paper reviews recent neuroimaging studies that report potential biomarkers in addiction treatment related to cue-reactivity, impulsivity, and cognitive control, as well as recent advances in neuroimaging that may facilitate efforts to determine reliable biomarkers. This important initial work has begun to identify possible mediators and moderators of treatment response, and multiple promising indices are being tested.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Volkow ND, Baler RD, Goldstein RZ. Addiction: pulling at the neural threads of social behaviors. Neuron. 2011;69(4):599–602. doi:10.1016/j.neuron.2011.01.027.
De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22(5):485–502.
Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. 2013;11:126. doi:10.1186/1741-7015-11-126.
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. AJ Psychiatry. 2010;167(7):748–51. doi:10.1176/appi.ajp.2010.09091379.
Drummond DC. What does cue-reactivity have to offer clinical research? Addiction. 2000;95 Suppl 2:S129–44.
Volkow ND, Baler RD. Brain imaging biomarkers to predict relapse in alcohol addiction. JAMA Psychiatry. 2013;70(7):661–3. doi:10.1001/jamapsychiatry.2013.1141.
Lauritzen M. Reading vascular changes in brain imaging: is dendritic calcium the key? Nat Rev Neurosci. 2005;6(1):77–85. doi:10.1038/nrn1589.
Laird AR, Fox PM, Price CJ, Glahn DC, Uecker AM, Lancaster JL, et al. ALE meta-analysis: controlling the false discovery rate and performing statistical contrasts. Hum Brain Mapp. 2005;25(1):155–64. doi:10.1002/hbm.20136.
Engelmann JM, Versace F, Robinson JD, Minnix JA, Lam CY, Cui Y, et al. Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies. Neuroimage. 2012;60(1):252–62. doi:10.1016/j.neuroimage.2011.12.024.
Chase HW, Eickhoff SB, Laird AR, Hogarth L. The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. Biol Psychiatry. 2011;70(8):785–93. doi:10.1016/j.biopsych.2011.05.025. Quantitative meta-analysis providing consensus across neuroimaging studies of cue-reactivity to drug and non-drug addiction-related cues and craving.
Kuhn S, Gallinat J. Common biology of craving across legal and illegal drugs—a quantitative meta-analysis of cue-reactivity brain response. Eur J Neurosci. 2011;33(7):1318–26. doi:10.1111/j.1460-9568.2010.07590.x.
Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol. 2013;18(1):121–33. doi:10.1111/j.1369-1600.2012.00464.x.
Tang DW, Fellows LK, Small DM, Dagher A. Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies. Physiol Behav. 2012;106(3):317–24. doi:10.1016/j.physbeh.2012.03.009.
Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y. Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. Neurosci Biobehav Rev. 2014;38:1–16. doi:10.1016/j.neubiorev.2013.10.013.
Seo D, Lacadie CM, Tuit K, Hong KI, Constable RT, Sinha R. Disrupted ventromedial prefrontal function, alcohol craving, and subsequent relapse risk. JAMA Psychiatry. 2013;70(7):727–39. doi:10.1001/jamapsychiatry.2013.762. fMRI study reporting a potential brain biomarker of alcohol cue-reactivity prospectively related to treatment relapse.
Beck A, Wustenberg T, Genauck A, Wrase J, Schlagenhauf F, Smolka MN, et al. Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. Arch Gen Psychiatry. 2012;69(8):842–52. doi:10.1001/archgenpsychiatry.2011.2026.
Janes AC, Pizzagalli DA, Richardt S, de Frederick B, Chuzi S, Pachas G, et al. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry. 2010;67(8):722–9. doi:10.1016/j.biopsych.2009.12.034.
LaConte SM, King-Casas B, Cinciripini PM, Eagleman DM, Versace F, Chiu PH. Modulating rt-fMRI neurofeedback interfaces via craving and control in chronic smokers. Neuroimage. 2009;47(Supplement 1):S45–S.
LaConte SM. Decoding fMRI brain states in real-time. Neuroimage. 2011;56(2):440–54. doi:10.1016/j.neuroimage.2010.06.052.
Garrison KA, Scheinost D, Worhunsky PD, Elwafi HM, Thornhill TA, Thompson E, et al. Real-time fMRI links subjective experience with brain activity during focused attention. Neuroimage. 2013;81:110–8. doi:10.1016/j.neuroimage.2013.05.030.
Stoeckel LE, Garrison KA, Ghosh S, Wighton P, Hanlon CA, Gilman JM, et al. Optimizing real time fMRI neurofeedback for therapeutic discovery and development. Neuroimage Clin. 2014;5:245–55. doi:10.1016/j.nicl.2014.07.002.
Canterberry M, Hanlon CA, Hartwell KJ, Li X, Owens M, LeMatty T, et al. Sustained reduction of nicotine craving with real-time neurofeedback: exploring the role of severity of dependence. Nicotine Tob Res: Off J Soc Res Nicotine Tob. 2013;15(12):2120–4. doi:10.1093/ntr/ntt122.
Hanlon CA, Hartwell KJ, Canterberry M, Li X, Owens M, Lematty T, et al. Reduction of cue-induced craving through realtime neurofeedback in nicotine users: the role of region of interest selection and multiple visits. Psychiatry Res. 2013;213(1):79–81. doi:10.1016/j.pscychresns.2013.03.003.
Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron. 2011;69(4):680–94. doi:10.1016/j.neuron.2011.01.020.
Robbins T, Curran H, de Wit H. Special issue on impulsivity and compulsivity. Psychopharmacology (Berl). 2012;219(2):251–2. doi:10.1007/s00213-011-2584-x.
Potenza MN, Sofuoglu M, Carroll KM, Rounsaville BJ. Neuroscience of behavioral and pharmacological treatments for addictions. Neuron. 2011;69(4):695–712. doi:10.1016/j.neuron.2011.02.009.
Stevens L, Verdejo-Garcia A, Goudriaan AE, Roeyers H, Dom G, Vanderplasschen W. Impulsivity as a vulnerability factor for poor addiction treatment outcomes: a review of neurocognitive findings among individuals with substance use disorders. J Subst Abuse Treat. 2014;47(1):58–72. doi:10.1016/j.jsat.2014.01.008.
Loree AM, Lundahl LH, Ledgerwood DM. Impulsivity as a predictor of treatment outcome in substance use disorders: review and synthesis. Drug Alcohol Rev. 2014. doi:10.1111/dar.12132.
Fineberg NA, Chamberlain SR, Goudriaan AE, Stein DJ, Vanderschuren LJ, Gillan CM, et al. New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity. CNS Spectrums. 2014;19(1):69–89. doi:10.1017/S1092852913000801.
Jupp B, Dalley JW. Behavioral endophenotypes of drug addiction: etiological insights from neuroimaging studies. Neuropharmacology. 2014;76:Pt B:487–97. doi:10.1016/j.neuropharm.2013.05.041.
Parvaz MA, Alia-Klein N, Woicik PA, Volkow ND, Goldstein RZ. Neuroimaging for drug addiction and related behaviors. Rev Neurosci. 2011;22(6):609–24. doi:10.1515/RNS.2011.055.
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A. 2011;108(37):15037–42. doi:10.1073/pnas.1010654108.
Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. AJ Psychiatry. 2011;168(6):634–41. doi:10.1176/appi.ajp.2010.10050748.
Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry. 2012;17(9):918–25. doi:10.1038/mp.2011.86.
Clark L, Stokes PR, Wu K, Michalczuk R, Benecke A, Watson BJ, et al. Striatal dopamine D(2)/D(3) receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage. 2012;63(1):40–6. doi:10.1016/j.neuroimage.2012.06.067.
Jia Z, Worhunsky PD, Carroll KM, Rounsaville BJ, Stevens MC, Pearlson GD, et al. An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence. Biol Psychiatry. 2011;70(6):553–60. doi:10.1016/j.biopsych.2011.05.008.
Yip SW, DeVito EE, Kober H, Worhunsky PD, Carroll KM, Potenza MN. Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: an exploratory study of relationships with abstinence during behavioral treatment. Drug Alcohol Depend. 2014;140:33–41. doi:10.1016/j.drugalcdep.2014.03.031.
Joos L, Goudriaan AE, Schmaal L, Fransen E, van den Brink W, Sabbe BG, et al. Effect of modafinil on impulsivity and relapse in alcohol dependent patients: a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2013;23(8):948–55. doi:10.1016/j.euroneuro.2012.10.004.
Schmaal L, Joos L, Koeleman M, Veltman DJ, van den Brink W, Goudriaan AE. Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients. Biol Psychiatry. 2013;73(3):211–8. doi:10.1016/j.biopsych.2012.06.032.
Carter CS, van Veen V. Anterior cingulate cortex and conflict detection: an update of theory and data. Cogn Affect Behav Neurosci. 2007;7(4):367–79.
Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013;64:452–63. doi:10.1016/j.neuropharm.2012.06.021.
Luijten M, Machielsen MW, Veltman DJ, Hester R, de Haan L, Franken IH. Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people with substance dependence and behavioural addictions. J Psychiatry Neurosci. 2014;39(3):149–69.
Nestor LJ, Ghahremani DG, Monterosso J, London ED. Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects. Psychiatry Res. 2011;194(3):287–95. doi:10.1016/j.pscychresns.2011.04.010.
Sorg SF, Taylor MJ, Alhassoon OM, Gongvatana A, Theilmann RJ, Frank LR, et al. Frontal white matter integrity predictors of adult alcohol treatment outcome. Biol Psychiatry. 2012;71(3):262–8. doi:10.1016/j.biopsych.2011.09.022.
Worhunsky PD, Stevens MC, Carroll KM, Rounsaville BJ, Calhoun VD, Pearlson GD, et al. Functional brain networks associated with cognitive control, cocaine dependence, and treatment outcome. Psychol Addict Behav. 2013;27(2):477–88. doi:10.1037/a0029092.
Marhe R, Luijten M, Franken IH. The clinical relevance of neurocognitive measures in addiction. Front Psychiatry. 2014;4:185. doi:10.3389/fpsyt.2013.00185.
Luo X, Zhang S, Hu S, Bednarski SR, Erdman E, Farr OM, et al. Error processing and gender-shared and -specific neural predictors of relapse in cocaine dependence. Brain. 2013;136(Pt 4):1231–44. doi:10.1093/brain/awt040. fMRI study reporting reduced activity in the dorsal anterior cingulate cortex during error processing that is related prospectively to cocaine relapse and earlier time to relapse.
Marhe R, van de Wetering BJ, Franken IH. Error-related brain activity predicts cocaine use after treatment at 3-month follow-up. Biol Psychiatry. 2013;73(8):782–8. doi:10.1016/j.biopsych.2012.12.016.
MacLeod CM. Half a century of research on the Stroop effect: an integrative review. Psychol Bull. 1991;109(2):163–203.
Potenza MN, Balodis IM, Franco CA, Bullock S, Xu J, Chung T, et al. Neurobiological considerations in understanding behavioral treatments for pathological gambling. Psychol Addict Behav. 2013;27(2):380–92. doi:10.1037/a0032389.
DeVito EE, Worhunsky PD, Carroll KM, Rounsaville BJ, Kober H, Potenza MN. A preliminary study of the neural effects of behavioral therapy for substance use disorders. Drug Alcohol Depend. 2012;122(3):228–35. doi:10.1016/j.drugalcdep.2011.10.002.
Brewer JA, Worhunsky PD, Carroll KM, Rounsaville BJ, Potenza MN. Pretreatment brain activation during Stroop task is associated with outcomes in cocaine-dependent patients. Biol Psychiatry. 2008;64(11):998–1004. doi:10.1016/j.biopsych.2008.05.024.
Krishnan-Sarin S, Balodis IM, Kober H, Worhunsky PD, Liss T, Xu J, et al. An exploratory pilot study of the relationship between neural correlates of cognitive control and reduction in cigarette use among treatment-seeking adolescent smokers. Psychol Addict Behav. 2013;27(2):526–32. doi:10.1037/a0032479.
Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, et al. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry. 2010;67(8):715–21. doi:10.1016/j.biopsych.2010.01.016.
Ghahremani DG, Tabibnia G, Monterosso J, Hellemann G, Poldrack RA, London ED. Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. Neuropsychopharmacology. 2011;36(5):950–9. doi:10.1038/npp.2010.233.
Goldstein RZ, Woicik PA, Maloney T, Tomasi D, Alia-Klein N, Shan J, et al. Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proc Natl Acad Sci U S A. 2010;107(38):16667–72. doi:10.1073/pnas.1011455107.
Li CS, Morgan PT, Matuskey D, Abdelghany O, Luo X, Chang JL, et al. Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients. Proc Natl Acad Sci U S A. 2010;107(32):14455–9. doi:10.1073/pnas.1002467107.
Sofuoglu M, Waters AJ, Poling J, Carroll KM. Galantamine improves sustained attention in chronic cocaine users. Exp Clin Psychopharmacol. 2011;19(1):11–9. doi:10.1037/a0022213.
Sofuoglu M, Carroll KM. Effects of galantamine on cocaine use in chronic cocaine users. Am J Addict. 2011;20(3):302–3. doi:10.1111/j.1521-0391.2011.00130.x.
Janes AC, Nickerson LD, Frederick Bde B, Kaufman MJ. Prefrontal and limbic resting state brain network functional connectivity differs between nicotine-dependent smokers and non-smoking controls. Drug Alcohol Depend. 2012;125(3):252–9. doi:10.1016/j.drugalcdep.2012.02.020.
Gordon EM, Devaney JM, Bean S, Vaidya CJ. Resting-state striato-frontal functional connectivity is sensitive to DAT1 genotype and predicts executive function. Cereb Cortex. 2013. doi:10.1093/cercor/bht229.
Muller VI, Langner R, Cieslik EC, Rottschy C, Eickhoff SB. Interindividual differences in cognitive flexibility: influence of gray matter volume, functional connectivity and trait impulsivity. Brain Struct Funct. 2014. doi:10.1007/s00429-014-0797-6.
Sutherland MT, McHugh MJ, Pariyadath V, Stein EA. Resting state functional connectivity in addiction: lessons learned and a road ahead. Neuroimage. 2012;62(4):2281–95. doi:10.1016/j.neuroimage.2012.01.117.
Camchong J, Stenger A, Fein G. Resting-state synchrony during early alcohol abstinence can predict subsequent relapse. Cereb Cortex. 2013;23(9):2086–99. doi:10.1093/cercor/bhs190.
McHugh MJ, Demers CH, Salmeron BJ, Devous Sr MD, Stein EA, Adinoff B. Cortico-amygdala coupling as a marker of early relapse risk in cocaine-addicted individuals. Front Psychiatry. 2014;5:16. doi:10.3389/fpsyt.2014.00016.
Konova AB, Moeller SJ, Tomasi D, Volkow ND, Goldstein RZ. Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. JAMA Psychiatry. 2013;70(8):857–68. doi:10.1001/jamapsychiatry.2013.1129. Resting state fMRI study of a pharmacological intervention for cocaine addiction demonstrating that changes in functional connectivity may be a potential mechanism of treatment effects.
Schmaal L, Goudriaan AE, Joos L, Kruse AM, Dom G, van den Brink W, et al. Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. Biol Psychiatry. 2013;73(8):789–95. doi:10.1016/j.biopsych.2012.12.025.
Cole DM, Oei NY, Soeter RP, Both S, van Gerven JM, Rombouts SA, et al. Dopamine-dependent architecture of cortico-subcortical network connectivity. Cereb Cortex. 2013;23(7):1509–16. doi:10.1093/cercor/bhs136.
Lerman C, Gu H, Loughead J, Ruparel K, Yang Y, Stein EA. Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function. JAMA Psychiatry. 2014;71(5):523–30. doi:10.1001/jamapsychiatry.2013.4091. Resting state fMRI connectivity study linking an index of large-scale network dynamics to craving and withdrawal during short-term abstinence, with implications for treatment.
Laird AR, Eickhoff SB, Rottschy C, Bzdok D, Ray KL, Fox PT. Networks of task co-activations. Neuroimage. 2013;80:505–14. doi:10.1016/j.neuroimage.2013.04.073.
Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, et al. Toward discovery science of human brain function. Proc Natl Acad Sci U S A. 2010;107(10):4734–9. doi:10.1073/pnas.0911855107.
Craddock RC, Jbabdi S, Yan CG, Vogelstein JT, Castellanos FX, Di Martino A, et al. Imaging human connectomes at the macroscale. Nat Methods. 2013;10(6):524–39. doi:10.1038/nmeth.2482.
Smith SM, Vidaurre D, Beckmann CF, Glasser MF, Jenkinson M, Miller KL, et al. Functional connectomics from resting-state fMRI. Trends Cogn Sci. 2013;17(12):666–82. doi:10.1016/j.tics.2013.09.016.
Kober H, Mende-Siedlecki P, Kross EF, Weber J, Mischel W, Hart CL, et al. Prefrontal-striatal pathway underlies cognitive regulation of craving. Proc Natl Acad Sci U S A. 2010;107(33):14811–6. doi:10.1073/pnas.1007779107.
Xu J, Kober H, Wang X, DeVito EE, Carroll KM, Potenza MN. Hippocampal volume mediates the relationship between measures of pre-treatment cocaine use and within-treatment cocaine abstinence. Drug Alcohol Depend. In press.
Ersche KD, Jones PS, Williams GB, Turton AJ, Robbins TW, Bullmore ET. Abnormal brain structure implicated in stimulant drug addiction. Science. 2012;335(6068):601–4. doi:10.1126/science.1214463. Diffusion tensor imaging study demonstrating common structural abnormalities in brain regions implicated in self-control in drug-addicted individuals and their non-addicted siblings, suggesting a potential neurocognitive endophenotype for drug addiction.
Wagner M, Schulze-Rauschenbach S, Petrovsky N, Brinkmeyer J, von der Goltz C, Grunder G, et al. Neurocognitive impairments in non-deprived smokers—results from a population-based multi-center study on smoking-related behavior. Addict Biol. 2013;18(4):752–61. doi:10.1111/j.1369-1600.2011.00429.x.
Morgenstern J, Naqvi NH, Debellis R, Breiter HC. The contributions of cognitive neuroscience and neuroimaging to understanding mechanisms of behavior change in addiction. Psychol Addict Behav. 2013;27(2):336–50. doi:10.1037/a0032435.
Robinson JL, Laird AR, Glahn DC, Lovallo WR, Fox PT. Metaanalytic connectivity modeling: delineating the functional connectivity of the human amygdala. Hum Brain Mapp. 2010;31(2):173–84. doi:10.1002/hbm.20854.
Yarkoni T, Poldrack RA, Nichols TE, Van Essen DC, Wager TD. Large-scale automated synthesis of human functional neuroimaging data. Nat Methods. 2011;8(8):665–70. doi:10.1038/nmeth.1635.
Wager TD, Lindquist M, Kaplan L. Meta-analysis of functional neuroimaging data: current and future directions. Soc Cogn Affect Neurosci. 2007;2(2):150–8.
Acknowledgments
This study was funded by the following grants: National Institute on Drug Abuse (NIDA) grants P50 DA09241, P20 DA027844, and R01 DA035058 and this work was supported by an award from the American Heart Association 14CRP18200010.
Compliance with Ethics Guidelines
ᅟ
Conflict of Interest
Kathleen A. Garrison declares that she has no conflict of interest.
Marc N. Potenza has received financial support or compensation for the following: Dr. Potenza has consulted for and advised Boehringer Ingelheim, Lundbeck, Ironwood, Shire, and INSYS; has consulted for Somaxon; has received research support from the National Institutes of Health, Veteran’s Administration, Mohegan Sun Casino, the National Center for Responsible Gaming, and Forest Laboratories, Pfizer, Ortho-McNeil, Oy-Control/Biotie, GlaxoSmithKline, and Psyadon pharmaceuticals; has participated in surveys, mailings, or telephone consultations related to drug addiction, impulse control disorders, or other health topics; has consulted for gambling entities, law offices, and the federal public defender’s office in issues related to impulse control disorders; provides clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; has performed grant reviews for the National Institutes of Health and other agencies; has guest-edited journal sections; has given academic lectures in grand rounds, CME events, and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Substance Use and Related Disorders
Rights and permissions
About this article
Cite this article
Garrison, K.A., Potenza, M.N. Neuroimaging and Biomarkers in Addiction Treatment. Curr Psychiatry Rep 16, 513 (2014). https://doi.org/10.1007/s11920-014-0513-5
Published:
DOI: https://doi.org/10.1007/s11920-014-0513-5